Skip to main content
. Author manuscript; available in PMC: 2019 Feb 16.
Published in final edited form as: J Vasc Res. 2018 Feb 16;55(2):98–110. doi: 10.1159/000486337

Fig. 2.

Fig. 2.

AAV8-PCSK9 treatment leads to disruption of cholesterol handling in both C57BL/6N and C57BL/6J mice, a Male C57BL/6N and C57BL/6J mice were treated with AAV8-PCSK9 virus (3 × 1010 vector genomes) for 2 weeks, and plasma cholesterol was determined by ELISA. b Mouse weight was monitored in AAV8-PCSK9 virus (3 × 1010 vector genomes)-infected mice fed a high-fat diet (HFD) for 8 weeks, or HFD for 4 weeks followed by co-treatment with HFD and MitoTEMPO (MT; 0.8 mg/kg/day) for the Final 4 weeks, c Plasma lipid analysis in C57BL/6N and C57BL/6J mice treated with AAV8-PCSK9 followed by HFD and HFD + MT. TC, total cholesterol; TG, triglycerides; LDL, low-density lipoprotein; HDL, high-density lipoprotein. Values are means ± SEM of 8 animals. a p < 0.05 versus 6N HFD; b p < 0.05 versus 6N HFD + MT.